CPRX - Catalyst Pharmaceuticals Getting Traction as Investors Evaluate the Competition
NEW YORK, NY / ACCESSWIRE / May 14, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX), a company focused on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome.
On May 7th, the company shares fell from $6.11 to $3.69 per share. After falling further, to $2.70 per share, CPRX has rebounded to the current level at $3.20.
More about the events that contributed to share volatility in this comprehensivereport READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/catalyst-pharmaceuticals/
The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. It has license agreements with New York University, the Feinstein Institute for Medical Research, and BioMarin Pharmaceutical Inc.; and collaboration agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets.
Find out what the analysts say about CPRX and more in this report READ MORE
Copy and paste to your browser may be required to view the report - https://tradersnewssource.com/catalyst-pharmaceuticals/
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://www.tradersnewssource.com.
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT: editor@tradersnewssource.com
SOURCE: Traders News Source
View source version on accesswire.com:
https://www.accesswire.com/545276/Catalyst-Pharmaceuticals-Getting-Traction-as-Investors-Evaluate-the-Competition